drugset / Trial / NCT02364635

Icosabutate - A Phase I, Single Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects

NCT02364635

Phase 1 Completed 32 enrolled Pronova BioPharma
RandomizedParallel-groupDouble-blind

Summary

PRC 4016 (Icosabutate) - A Phase I, Single-Blind, Placebo Controlled, Single Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects Objective: * To assess the safety and tolerability of single ascending oral doses of icosabutate in healthy subjects * To evaluate the pharmacokinetic (PK) parameters of icosabutate in healthy subjects

Timeline

Start
2015-02
Primary completion
2015-08
Completion
2015-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Icosabutate Small molecule Oral

Indications

No indication recorded.